Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China


  • The P-III study involves assessing of SCB-808 (SC) vs Enbrel (SC) in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) to evaluate its safety, efficacy and PK
  • The company utilizes its Trimer-Tag technology platform to develop novel therapies targeting trimerization-dependent pathways and is also leveraging its cGMP biomanufacturing capabilities to develop biosimilars
  • SCB-808 is mAb being developed as a prefilled syringe ready-for-injection self-administered for the treatment of rheumatoid arthritis and other autoimmune diseases

Click here to read full press release/ article | Ref: GlobeNewswire| Image: Signbox